May 27, 2020
Synthetic Biologics Enters into Exclusive Option to License Intellectual Property for Use of SYN-020 to Treat and Prevent Age-Related Metabolic and Inflammatory Diseases
May 05, 2020
Synthetic Biologics Reports 2020 First Quarter Operational Highlights and Financial Results
Jan 07, 2020
Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients
Nov 27, 2019
Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan
Nov 04, 2019
Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results
Oct 28, 2019
Synthetic Biologics to Report 2019 Third Quarter Operational Highlights and Financial Results on November 4, 2019
Sep 26, 2019
Synthetic Biologics Strengthens U.S. Patent Coverage of SYN-010, Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
Aug 01, 2019
Synthetic Biologics to Report 2019 Second Quarter Operational Highlights and Financial Results on August 8, 2019
Jul 01, 2019
Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards
May 08, 2019
Synthetic Biologics Reports First Quarter 2019 Operational Highlights and Financial Results
Apr 30, 2019
Synthetic Biologics to Report 2019 First Quarter Operational Highlights and Financial Results on May 8, 2019
Feb 27, 2019
Synthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results
Feb 19, 2019
Synthetic Biologics to Report 2018 Year End Operational Highlights and Financial Results on February 27, 2019
Jan 03, 2019
Synthetic Biologics Announces First Two Patients Enrolled in Phase 2b Investigator-Sponsored
Nov 21, 2018
Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 (ribaxamase) Development
Nov 08, 2018
Synthetic Biologics Reports Third Quarter 2018 Operational Highlights and Financial Results
Oct 30, 2018
Synthetic Biologics to Report Third Quarter 2018 Operational Highlights and Financial Results on November 8, 2018
Oct 11, 2018
Synthetic Biologics Prices $18,000,000 Public Offering
Sep 06, 2018
Synthetic Biologics Announces Agreement with Cedars-Sinai Medical Center for an Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C
Aug 30, 2018
Synthetic Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference